The failure of a pharma content strategy at scale has one simple reason: the volume of assets scaled by a team before the system planning, reviewing, localizing, distributing, and measuring assets scales with that asset volume. In biopharma, such a divide manifests itself quickly. Field teams consume less than half the content in less than half the number of HCP touches, and almost 80 percent of approved content is infrequently or never utilized. Simultaneously, promotional content should comply with FDA and broader regulatory requirements for honest, balanced communication, indicating that any weak handoff, late change to a claim, or unclear ownership of regulatory requirements leads to delays and rework.
That is why a modern pharma content strategy cannot be a publishing calendar with better templates. It has to be an operating model. When strategy, review, content operations, and field execution move on separate tracks, scale produces waste, not reach.
Why pharma content strategy breaks when output outruns use
Most teams think that scale requires an increase in the number of emails, a greater number of detail aids, a greater number of websites, a greater number of variants, and more localized edits. The statistics are the opposite. According to Veeva, HCP engagement driven by content can over twice the rate of treatment adoption, but field teams continue to deliver content in less than half of interactions, with almost 80 percent of approved content used infrequently or not at all. The fact that the mismatch exists indicates that it is not a lack of content. There is poor congruence between the design and actual application.
A literal interpretation of such a benchmark would draw an even more difficult conclusion: numerous pharma teams are ramping up production and neglecting selection. That is, they are accumulating additional assets than the business can mobilize, control, or know about. Deloitte makes a similar point from the operating-model side, arguing that life sciences teams need an integrated content supply chain that supports speed, consistency, and resource control rather than fragmented production.
A quick math check
Here is a simple planning model based on the Veeva benchmark.
| Scenario | Value | What it means |
| Assets approved in a quarter | 200 | Full review effort is spent on all 200 |
| Rarely or never used | 160 | Based on the “nearly 80% unused” benchmark |
| Used in the field | 40 | Only one in five assets creates practical value |
This does not prove every company wastes 80% of its budget. It does show why scale can feel busy and still underperform. When usage feedback is weak, volume becomes a false comfort metric.
The real slowdown starts before MLR review
The second failure mode is medical, legal, and regulatory review. There is a reason why there is review. The FDA regulation of prescription drug promotion is constructed on the basis of honest, fair, and non-deceptive communication and the existing U.S. regulations provide a fair balance and present risk information properly. The issue is not whether or not there is a review. The issue is that the review is turned into a de facto project manager of all assets.
EY reports a similar order of magnitude, citing 24 average days to approval in current MLR processes. That tells us the real drag is often upstream coordination, not endless formal rejection rounds.
Where the clock usually breaks
- Claims and references are assembled too late.
- Brand, medical, legal, and regulatory teams comment in different systems.
- Content enters review before channel requirements are fully defined.
- Local markets request edits after global approval.
- Teams review the whole assets again instead of reusing approved modules.
These are common pharma content strategy mistakes, and they are usually process mistakes wearing a content label. Veeva also notes that companies with optimized MLR workflows have seen a 57% drop in review cycle times and a 55% reduction in time spent in review meetings. That suggests the bottleneck is fixable when governance is clear and the workflow has one source of truth.
Why Pharma Content Strategies Fail Across Markets and Channels
Scale is also broken when teams attempt to operate omnichannel programs with channel-specific content stacks. Email copy is written by one team. The other is the owner of sales aids. Another edits websites asserts. All three are then rebuilt by a local market. The outcome is paper-global and practice-fragmented.
According to ZS, pharma scaling remains focused on the big markets and core capabilities, but further advanced capabilities like content personalization and coordination are still at an early stage. According to the same analysis, cross-functional funding, local capability transitions, and operational issues are the significant obstacles. That is what most launch teams are accustomed to: a strategy may seem fine in the global deck and a crash failure when it comes to execution because no one has ever thought of the local operating path.
A more appropriate test is the following: is it possible to transfer one approved claim, one fair-balance block, and one approved reference set across email, rep-triggered content, websites, remote detailing, and local variants without rebuilding manually? In case the answer is no, the pharmaceutical content strategy is not scaling. It is duplicating. It is in this form of integrated operating structure that the supply chain model of life sciences at Deloitte contends, with reduced agency expenditure and enhanced uniformity of channels.
The mistakes pharma teams repeat at scale
The pattern is usually familiar:
- Teams fund creation but underfund content operations.
- They measure output, not usage.
- They treat MLR as a gate at the end instead of a design rule at the start.
- They localize by rewriting full assets instead of adapting approved modules.
- They build channel assets first and audience journeys second.
- They store claims, references, and annotations in different places.
- They assume more personalization always means more content.
That last point deserves care. Veeva’s 2025 analysis, including commentary from Genentech’s content leadership, makes the same case in industry terms: personalization should serve business goals, while volume is only a side effect. That is a useful correction for teams chasing AI-assisted speed without fixing decision rules.
Comparison: broken model vs scaled model
| Broken model | Scaled model |
| Asset-first planning | audience-and-use-case planning |
| Whole-piece review | module and claim reuse |
| Local rework after approval | reusable global core with controlled adaptation |
| Success = volume shipped | Success = content used, approved, and reused |
What good content operations look like when pharma content strategy is built to scale
A sound pharma content strategy has five traits.
- It starts with approved claims, evidence, and audience rules.
- It separates global core content from local adaptation.
- It uses modular blocks so teams do not re-review the same material in full.
- It tracks usage and retirement, not only approval.
- It gives one team clear ownership for content operations.
Here it is: content operations, which is the actual driving force. This layer that determines intake policies, asset types, modular standards, metadata, workflow states, localization paths, reuse policies, and measurements is known as content ops. Without that, even intelligent teams end up haggling over essentials on any project. Veeva and Deloitte mention governance, standardized processes, automation and single source of truth as the practical solutions that reduce the cycle time and waste.
This is seen in a small team exercise. Select one email, one sales aid and one landing page with the same product message. Then ask three questions:
- Which claim block is reused word-for-word?
- Which references support all three assets?
- Which risk language must remain fixed across all three?
In case three distinct teams provide different answers to those questions three times, there is no problem with the quality of copying. The problem is system design.
A smarter way to test whether your content can scale
Before adding another channel or AI layer, ask this short checklist:
- Can we trace every claim to one approved evidence source?
- Can we tell which 20% of assets drive most real usage?
- Can local teams adapt without reopening the whole asset?
- Can reviewers comment inside one controlled workflow?
- Can we retire outdated content fast?
Scale is likely to bring about queue time, review friction, and waste of content when the answer to three or more is a no. That is where pharma content strategy needs to shift off editorial planning onto operating discipline.
From content volume to content use
Why are pharma content strategies not scalable? As scale can reveal all the weak assumptions. It reveals the disconnect between acceptance and utilization. It reveals the price of reviewing late. It reveals local-market friction. And it reveals the existence of a real reuse, governance, and distribution system in the company. The victorious teams do not post the most. It is they which carry approved scientific material through the business with less labor, more reusing, and closer relation to field action.
